Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02556710
Other study ID # AP-003-B
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 2015
Est. completion date June 2016

Study information

Verified date August 2022
Source Ampio Pharmaceuticals. Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the efficacy and safety of an intra-articular injection of AMPION™ in adults with pain due to osteoarthritis of the knee


Description:

A Randomized, Placebo-Controlled, Double-Blind Study To Evaluate The Efficacy And Safety Of An Intra-Articular Injection Of AMPION™ In Adults With Pain Due to Osteoarthritis Of The Knee The primary trial objective is to evaluate the efficacy of 4 mL of AMPION™ versus 4 mL placebo intra-articular (IA) injection in improving knee pain, when applied to patients suffering from OA of the knee. The secondary trial objective is evaluation of the safety of an intra-articular injection of AMPION™.


Recruitment information / eligibility

Status Completed
Enrollment 480
Est. completion date June 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender All
Age group 40 Years to 85 Years
Eligibility Inclusion Criteria: - Able to provide written informed consent to participate in the study; - Willing and able to comply with all study requirements and instructions of the site study staff; - Male or female, 40 years to 85 years old (inclusive); - Must be ambulatory; - Index knee must be symptomatic for greater than 6 months with a clinical diagnosis of OA and supported by radiological evidence (Kellgren Lawrence Grade II, III, or IV) read by a central reader; - WOMAC 5-point Likert pain subscale <1.5 in the contralateral knee; - Moderate to moderately-severe OA pain in the index knee (rating of at least 1.5 on the WOMAC Index 3.1 5-point Likert Pain Subscale); - Moderate to moderately-severe OA pain in the index knee (even if chronic doses of nonsteroidal anti-inflammatory drug (NSAID), which have not changed in the 4 weeks prior to screening, have been/are being used); - Ability to discontinue NSAID use at Screening visit and/or 72 hours prior to the Baseline visit and for the duration of the clinical study (low dose Aspirin is allowed during the study); - No analgesia (including acetaminophen [paracetamol]) taken 24 hours prior to an efficacy measure; - No known clinically significant liver abnormality (e.g. cirrhosis, transplant, etc.). Exclusion Criteria: - As a result of medical review and screening investigation, the Principal Investigator considers the patient unfit for the study - A history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion) - A history of allergic reactions to excipients in 5% human albumin (N-acetyltryptophan, sodium caprylate) - Presence of tense effusions - Inflammatory or crystal arthropathies, acute fractures, history of aseptic necrosis or joint replacement in the affected knee, as assessed locally by the Principal Investigator - Isolated patella femoral syndrome, also known as chondromalacia - Any other disease or condition interfering with the free use and evaluation of the index knee for the duration of the trial (e.g. cancer, congenital defects, spine osteoarthritis) - Major injury to the index knee within the 12 months prior to screening - Severe hip osteoarthritis ipsilateral to the index knee - Any pain that could interfere with the assessment of index knee pain (e.g. pain in any other part of the lower extremities, pain radiating to the knee) - Any pharmacological or non-pharmacological treatment targeting OA started or changed during the 4 weeks prior to randomization or likely to be changed during the duration of the study - Pregnancy or planning to become pregnant during the study. - Use of the following medications: - No IA injected pain medications in the study knee during the study - No analgesics containing opioids. - NSAIDs are not permitted during the study; acetaminophen is available as a rescue medication during the study from the provided supply. - No topical treatment on osteoarthritis index knee during the study - No significant anticoagulant therapy (e.g. Heparin or Lovenox) during the study (treatment such as low dose Aspirin and Plavix are allowed) - No systemic treatments that may interfere with safety or efficacy assessments during the study - No immunosuppressants - No use of corticosteroids - No human albumin treatment in the 3 months before randomization or throughout the duration of the study

Study Design


Intervention

Biological:
4 mL injection of AMPION™
4 mL Injection of Ampion
Drug:
4 mL injection of Placebo
4 mL Injection of Placebo

Locations

Country Name City State
United States Ampio Pharmaceuticals Englewood Colorado

Sponsors (1)

Lead Sponsor Collaborator
Ampio Pharmaceuticals. Inc.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Cole B, McGrath B, Salottolo K, Bar-Or D. LMWF-5A for the Treatment of Severe Osteoarthritis of the Knee: Integrated Analysis of Safety and Efficacy. Orthopedics. 2018 Jan 1;41(1):e77-e83. doi: 10.3928/01477447-20171114-05. Epub 2017 Nov 21. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Knee Pain Mean Change in WOMAC A Pain (Western Ontario and McMaster Universities Arthritis Index) score from Baseline to 12 weeks. 5-point Likert scale (0=none to 4=extreme). A negative difference constitutes a decrease in pain with a greater negative value indicating a greater reduction in pain. Scored at Baseline and 12 weeks
Secondary Change in Knee Function Mean change in WOMAC C function score (Western Ontario and McMaster Universities Arthritis Index) from Baseline to 12 weeks. 5-point Likert scale indicating limitation of function (0=none to 4=extreme). A greater negative value indicates a improvement in function. Scored at Baseline and 12 Weeks
See also
  Status Clinical Trial Phase
Completed NCT03277066 - A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis Phase 2
Recruiting NCT03090698 - Outcomes of Injections in Patients Waiting for Total Knee Replacement Phase 4
Withdrawn NCT02237846 - Clinical Study of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC) for Treatment of Osteoarthritis Phase 1/Phase 2
Completed NCT02242435 - A Multiple Injection Study Evaluating Safety and Efficacy of Ampion in Osteoarthritis Phase 3
Completed NCT02096393 - Patient Specific Instrumentation in TKR N/A
Completed NCT01849445 - Targeted Rehabilitation to Improve Outcome After Knee Replacement- A Physiotherapy Study N/A
Completed NCT01704157 - A Prospective Study Evaluating the Treatment of Knee Osteoarthritis With the Cryo-Touch III Device N/A
Active, not recruiting NCT01374230 - Long-Term Multicenter Evaluation of the E1® Tibial Bearing N/A
Not yet recruiting NCT01270412 - Platelet Rich Plasma (PRP) as a Treatment for Knee Osteoarthritis PRP as a Treatment for Knee Osteoarthritis Phase 2/Phase 3
Completed NCT02156440 - Cross-over Study of the Efficacy and Safety of SierraSil Joint Formula 14 in Osteoarthritis of the Knee Phase 2
Completed NCT01410409 - Structured Treatment of Osteoarthritis of the Knee With or Without Total Knee Replacement N/A
Completed NCT01207115 - A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee Phase 2
Completed NCT01331278 - A Comparative Study of Knee Systems Phase 4
Completed NCT00988091 - Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee Phase 3
Completed NCT00970008 - Exploring Massage Benefits for Arthritis of the Knee Phase 2
Completed NCT00531427 - Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee Phase 3
Completed NCT00792727 - HKT-500 in Adult Patients With Osteoarthritis (OA) Knee Pain Phase 3
Completed NCT00449696 - Gel-200 Versus Placebo in Osteoarthritis of the Knee Phase 3
Completed NCT04145011 - Coolief Cooled Radiofrequency vs. Conventional Radiofrequency to Manage OA Knee Pain N/A
Completed NCT01430559 - Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee N/A